Award
National Institute of Neurological Disorders and Stroke 5U44NS129628-04
Preclinical and Early Clinical Development of a Novel Drug for On-Demand Voiding
Recipient
DIGNIFY THERAPEUTICS, LLC
Award Amount
$199,520.00
Ceiling
$199,520.00
Awarded
May 05, 2026
Identifier
5U44NS129628-04
This award funds the preclinical and early clinical development of DTI-117, a drug targeting Neurokinin 2 receptors to restore voluntary bowel and bladder control in patients with neurological disorders. The project includes efficacy and safety studies, drug manufacturing, and IND submission for clinical trials.
Description
The project aims to develop a novel pharmaceutical treatment to produce efficient and safe on-demand voiding in people with bowel and bladder retention disorders due to spinal cord injury and diseases such as multiple sclerosis, diabetes, and aging-related complications. The grant will fund FDA-mandated nonclinical studies to enable submission of an Investigational New Drug Application (IND) for future clinical studies.